Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 20/20 | 0.81 |
| ▸ | BCR known ✓ | P11274 | 17/20 | 0.81 |
| ▸ | KIT known ✓ | P10721 | 9/20 | 0.81 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.76 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.76 |
| ▸ | BRAF known ✓ | P15056 | 1/20 | 0.76 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.76 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.76 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.76 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.81 |
| ▸ | RAD52 | P43351 | 1/20 | 0.81 |
| ▸ | LYN | P07948 | 4/20 | 0.76 |
| ▸ | ABL2 | P42684 | 4/20 | 0.76 |
| ▸ | SRC | P12931 | 2/20 | 0.76 |
| ▸ | SYK | P43405 | 2/20 | 0.76 |
| ▸ | PLK4 | O00444 | 1/20 | 0.76 |
| ▸ | DDX3X | O00571 | 1/20 | 0.76 |
| ▸ | GAK | O14976 | 1/20 | 0.76 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.76 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3860712 | 0.97 | ABL1 (0.80) | ABL1BCRKITPDGFRARAD52 | |
| SCHEMBL3860717 | 0.97 | ABL1 (0.85) | ABL1BCRKITPDGFRARAD52 | |
| SCHEMBL3859467 | 0.95 | ABL1 (0.75) | ABL1BCRKITPDGFRARAD52 | |
| SCHEMBL2624943 | 0.94 | ABL1 (0.84) | ABL1BCRKITPDGFRARAD52 | |
| SCHEMBL3859559 | 0.93 | ABL1 (0.94) | ABL1BCRKITPDGFRARAD52 | |
| SCHEMBL3863215 | 0.92 | ABL1 (0.74) | ABL1BCRKITPDGFRARAD52 | |
| SCHEMBL3863321 | 0.91 | ABL1 (0.84) | ABL1BCRKITPDGFRARAD52 | |
| SCHEMBL3868282 | 0.91 | ABL1 (0.79) | ABL1BCRKITPDGFRARAD52 | |
| SCHEMBL3859449 | 0.91 | ABL1 (0.79) | ABL1BCRKITPDGFRARAD52 | |
| SCHEMBL3867814 | 0.90 | ABL1 (0.88) | ABL1BCRKITPDGFRARAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595323-B2 | N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof | IL YANG PHARM. CO., LTD. (KR) | 2009-09-29 | — | — | US | disclosed |
| US-20040248918-A1 | Anticancer agents | IL YANG PHARM. CO., LTD. | 2004-12-09 | — | — | US | disclosed |
| WO-2004099186-A1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | IL YANG PHARM CO., LTD. (KR) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248918-A1 | Anticancer agents | BRDT, CHIA, RNASE1 | ABL1 1106/4885BCR 2730/4885KIT 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.